You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS1 Rearrangement

Showing 1 - 25 of 1,288
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)

Recruiting
  • ROS1 Rearrangement Non-small Cell Lung Cancer
  • ALK Rearrangement Non-small Cell Lung Cancer
  • ShangHai, Shanghai, China
    Shanghai Chest hospital affiliated to Shanghai jiao tong univers
Sep 14, 2021

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +18 more
Oct 6, 2022

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

Recruiting
  • Lung Cancer
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 7, 2021

NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement Trial in France

Completed
  • NSCLC
  • +2 more
    • Aix en Provence, France
    • +25 more
    Sep 24, 2021

    NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

    Recruiting
    • NSCLC Stage IIIB
    • +4 more
    • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
    • Carboplatin + Pemetrexed + Atezolizumab
    • Angers, France
    • +30 more
    Jun 7, 2021

    First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

    Recruiting
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • Goyang-Si, Gyeonggi-do, Korea, Republic of
      National Cancer Center
    Apr 4, 2022

    Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Tumor-infiltrating Lymphocytes (TIL)
    • +5 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

    Recruiting
    • Protein Kinase Inhibitors
    • +3 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Nov 9, 2023

    NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

    Not yet recruiting
    • Non-Small Cell Lung Cancer(NSCLC)
    • WX-0593 Tablets
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Mar 1, 2023

    Lung Cancer, ROS1 Gene Rearrangement Trial in Shanghai (X-396 Capsule)

    Unknown status
    • Lung Cancer
    • ROS1 Gene Rearrangement
    • X-396 Capsule
    • Shanghai, Shanghai, China
      Chest hospital affiliated to Shanghai jiao tong university
    Jan 6, 2020

    NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Department of Thoracic Surgery and Oncology, The First Affiliate
    Mar 17, 2023

    Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

    Not yet recruiting
    • Locally Advanced Solid Tumor
    • Metastatic Solid Tumor
    • Providence, Rhode Island
      Rhode Island Hospital, Brown University
    Mar 2, 2023

    Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)

    Recruiting
    • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's hospital
    May 31, 2022

    Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)

    Completed
    Has Results
    • Lung Cancer, Nonsmall Cell
    • Aurora, Colorado
      University of Colorado Denver
    Jan 19, 2022

    Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

    Withdrawn
    • Advanced Malignant Neoplasm
    • +10 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 15, 2022

    Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1

    Completed
    • Lung Cancer ROS Translocated
      • Créteil, France
        CHI Créteil
      Nov 19, 2021

      Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

      Withdrawn
      • Non-Small Cell Lung Cancer
      • InVisionFirst-Lung ctDNA assay
      • Los Angeles, California
      • +2 more
      Sep 16, 2022

      Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

      Recruiting
      • Cancer
      • +15 more
      • Data collection and quality of life questionnaire
      • Graz, Austria
      • +40 more
      Jul 27, 2021

      Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

      Recruiting
      • Locally Advanced or Metastatic Solid Tumors
      • Locally Advanced or Metastatic Non-small Cell Lung Cancer
      • XZP-5955 tablets
      • Beijing, Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      May 17, 2022

      Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

      Recruiting
      • Soft Tissue Sarcoma
      • +2 more
      • Blood and tumor samples
      • Clermont-Ferrand, France
      • +9 more
      Dec 8, 2021

      Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,

      Recruiting
      • Invasive Lobular Breast Carcinoma
      • +2 more
      • Brussels, Belgium
      • +9 more
      May 4, 2022

      Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

      Active, not recruiting
      • Advanced Lymphoma
      • +5 more
      • Philadelphia, Pennsylvania
        ECOG-ACRIN Cancer Research Group
      Feb 4, 2022